{"id":"placebo-for-abt-333","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish baseline efficacy and safety of an investigational drug by comparison. In Phase 3 trials for ABT-333, the placebo arm allows researchers to distinguish true drug effects from natural disease progression and placebo response. Any observed benefits in the placebo group reflect non-pharmacological factors such as patient expectation and natural recovery.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:50.926Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03003338","phase":"PHASE4","title":"MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2017-10-24","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT01715415","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Chronic Hepatitis C Infection","enrollment":395},{"nctId":"NCT01716585","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Chronic Hepatitis C Infection","enrollment":636},{"nctId":"NCT01767116","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":"Chronic Hepatitis C Infection","enrollment":419},{"nctId":"NCT01833533","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":305},{"nctId":"NCT00851890","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-03","conditions":"Chronic Hepatitis C Virus Infection","enrollment":30},{"nctId":"NCT00696904","phase":"PHASE1","title":"Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2008-06","conditions":"HCV Infection","enrollment":133},{"nctId":"NCT02517515","phase":"PHASE3","title":"ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-07","conditions":"Hepatitis C Virus (HCV)","enrollment":650},{"nctId":"NCT01074008","phase":"PHASE2","title":"A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":"Hepatitis C, HCV, Chronic Hepatitis C Infection","enrollment":74},{"nctId":"NCT00919490","phase":"PHASE1","title":"A Study of Single Dose of ABT-333 in Healthy Male Adults","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-06","conditions":"HCV Infections","enrollment":39},{"nctId":"NCT00895102","phase":"PHASE1","title":"Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-04","conditions":"HCV Infection","enrollment":34},{"nctId":"NCT00909636","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-05","conditions":"HCV Infection","enrollment":24},{"nctId":"NCT00768690","phase":"PHASE1","title":"A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-10","conditions":"HCV Infection","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for ABT-333","genericName":"Placebo for ABT-333","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}